Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02654158

Enrollment

2400

Registered

2016-01-13

Start date

2013-08-31

Completion date

2017-05-31

Last updated

2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Upper Respiratory Infection

Keywords

acute upper respiratory infection

Brief summary

Phase IV trial,Single-arm, multi-centre clinical trial to assess the efficacy and safety of Fuganlin Oral Liquid in children with acute upper respiratory infection

Detailed description

Low-dose group of Fuganlin Oral Liquid:dosage from 5 to 10 ml; High-dose group of Fuganlin Oral Liquid:dosage from 10 to 20 ml; Treatment for 1 week.Patients who were recovered within 1 week can withdrawal at any time. Research purpose: 1. Evaluate the safety and efficacy of Fuganlin oral Liquid when expanding the designated indications(Qi deficiency wind-heat syndrome to wind-heat syndrome) . 2. Explore the relationship between elevated white blood cells and efficacy, age and efficacy, dose and efficacy,While treating with Fuganlin oral Liquid in children with acute respiratory infection. 3. Observe the antiviral and immunomodulatory effects of Fuganlin oral Liquid. 4. Provide data to support the clinical medicine guidelines and labels amendment of Fuganlin oral Liquid.

Interventions

DRUGLow-dose of Fuganlin Oral Liquid

less than 1 years old: 5mL each time and three times a day 1\ 3 years old: 10mL each time and three times a day 4\ 6 years old: 10mL each time and four times a day 7\ 12 years old: 10mL each time and five times a day

DRUGHigh-dose of Fuganlin Oral Liquid

less than 1 years old: 10mL each time and three times a day 1\ 3 years old: 20mL each time and three times a day 4\ 6 years old: 20mL each time and four times a day 7\ 12 years old: 20mL each time and five times a day

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 12 Years

Healthy volunteers

Inclusion criteria

1. Patients diagnosed as acute upper respiratory infection. 2. Patients with acute upper respiratory infection diagnosed as Tradition Chinese Medicine syndrome qi deficiency wind-heat. 3. Patients aged 1 to 12 years old. 4. Parents or guardians agreed to participate this study and signed the informed consent.

Exclusion criteria

1. Patients whose total numbers of white blood cells around above1.3ULN. 2. Patients diagnosed as suppurative tonsillitis, otitis media, bronchitis and other airway. 3. Patients allergic to the test drug. 4. Serious cardiovascular, liver,kidney and other primary systemic diseases. 5. Patients should not be included in group according to investigator's evaluation.

Design outcomes

Primary

Measure	Time frame	Description
Duration of cold symptoms	Defined as the time from the onset of the cold to the time achieve a cold cure standard,time average 1 to 7 days	Cold diagnostic criteria： 1. Nasal congestion, runny nose, sneezing, itchy throat, or pain, cough 2. The chills, fever, no sweat or less sweat, headache, limb sour 3. The total numbers of normal or low white blood cells, neutropenia, relative increase in lymphocytes. Cold cure criteria: 1. Fever, aversion to wind individual symptoms disappeared 2. Nasal congestion, runny nose, sore throat, cough individual symptoms disappeared

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026